Strains, plasmids, and PCR manipulations. Standard media and methods were used for plasmid manipulations (
2) and yeast genetic manipulations (
13). The
S. cerevisiae strains used in this study are listed in Table , and the plasmids used are listed in Table .
To generate the
GAL1p-CDC42 allele, the oligonucleotides DJL42-1 (5′-
GC CGGAACTCAAAAGGGTAATTTCGTGAAAAACAATCATCGACTACGT CGTAAGGCCG-3′ and DJL42-2 (5′-TCAGTAGAAGGATATGACAAGG G-3′) were used to amplify a DNA fragment containing the
LEU2 gene, the
GAL1 promoter, and flanking
CDC42 sequences using PCR with the plasmid pGAL-CDC42Sc (
55) as a template (the underlined sequence in DJL42-1 is the genomic sequence 733 to 693 bp upstream of the
CDC42 start codon, whereas in DJL42-2 it is the reverse complement of nucleotides 204 to 226 in the
CDC42 open reading frame). The PCR fragment was transformed into DLY1, replacing the endogenous
CDC42 promoter (1 to 693 bp upstream of the start codon) with
LEU2 and the
GAL1 promoter, creating DLY3067. Leu
+ transformants were selected on galactose-containing plates, and promoter replacement was confirmed by the inability to grow on dextrose-containing plates (
GAL1 promoter off) and by PCR.
To generate the
cdc42::
URA3 null allele, the oligonucleotides CDC42-5′ (5′-CTATTTTCCTGAGGAGATAGGTTAACAAACGAATTAGAGAAGGCGCGTTTCGGTGATGAC-3′) and CDC42-3′ (5′-GAGGCTCCAAGGCGGCCACGATAGCTTCATCGAATACATTCTTTCCTGATGCGGTATTTTC-3′) were used to amplify the
URA3 gene using PCR with the plasmid pRS306 (
45) as a template. The PCR product was transformed directly into a yeast strain containing an additional copy of
CDC42 under the control of the
GAL1 promoter (in this case, integrated at
LEU2 using pDLB377, a YIp derivative of pGAL-
CDC42Sc [
55] generated by replacing the
ClaI fragment containing pRS315 vector sequences with the corresponding fragment from pRS305 [
45]). Ura
+ transformants were selected on galactose-containing plates to replace the endogenous copy of
CDC42 (from 45 bp upstream to 494 bp downstream of the start codon, removing all but the last 26 codons) with
URA3, generating strain MOSY0090. Transformants were tested for the inability to grow on dextrose-containing plates (
GAL1 promoter off), and gene replacement was confirmed by PCR.
cdc42-md1 was integrated into the endogenous
CDC42 locus by one-step replacement of the
cdc42::URA3 allele. A 1.2-kb
EcoRI fragment containing
cdc42-md1 was excised from pMOSB36 and transformed into MOSY0090 together with the
TRP1-marked plasmid, pRS314 (
45). Trp
+ transformants were selected on galactose-containing plates and then selected for the ability to grow on dextrose-containing plates (
GAL1 promoter off) containing 5-fluoroorotic acid (to kill
URA3 cells [
7]), and gene replacement was confirmed by PCR.
cdc42-md1 was then back-crossed to separate it from the
leu2::GAL1p-CDC42::LEU2 present in MOSY0090, generating MOSY0178.
To create pDLB643, the template for PCR mutagenesis of
CDC42, the
CDC42 promoter and coding sequences were fused to the transcription terminator sequences from
TDH3. The oligonucleotides DJL42-3 (5′-CCACCGTCGATTCAAGGGTC-3′) and DJL42-4 (5′-AGATCTCTGAGCAAAGCG-3′) were first used to amplify
CDC42 (from 366 bp upstream of the start codon to 30 bp downstream of the stop codon) using the plasmid YEp351-CDC42 (
55) as a template, and this fragment was cloned into pCR2.1 (Invitrogen, Carlsbad, Calif.) to make pCR42-3/4. The
TDH3 transcription terminator sequences (a 900-bp
BamHI/
BglII fragment from pAB23BX [
43]) were then cloned into the
BamHI site of pCR42-3/4 to make pDLB643. A 2-kb
XhoI/
BamHI fragment from pDLB643 was also cloned into the corresponding sites of pRS316 (
45) to make pMOSB55.
To create pDLB644, the recipient plasmid for expressing the mutant alleles of
CDC42,
CDC42 promoter sequences were fused (via a unique
BglII site) to the transcription terminator sequences from
TDH3 and cloned into the vector pRS316 (
45). The oligonucleotides DJL42-3 (see above) and DJL42-5 (5′-
AGATCTGGAAGACCTAATACG-3′; the
BglII site is underlined) were used to amplify a DNA fragment containing the
CDC42 promoter (1 to 366 bp upstream of the start codon) using the plasmid YEp351-CDC42 (
55) as a template, and this fragment was cloned into pCR2.1 (Invitrogen) to make pCR42-3/5. The
TDH3 transcription terminator sequences were then cloned into the
BamHI site of pCR42-3/5 to create pDLB642. The 1.2-kb
XhoI/
BamHI fragment from pDLB642 was then cloned into the corresponding sites of pRS316 (
45) to make pDLB644. pDLB644 was linearized by digestion with
BglII and transformed into yeast cells together with the mutagenized
CDC42 PCR products which underwent gap repair to yield Ura
+ colonies.
The cdc42-V36A, cdc42-Y40C, and cdc42-D57Y alleles were constructed using the ExSite PCR-based site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). To generate pMOSB16 (cdc42-V36A), PCR was performed using the oligonucleotides cdc-4 (5′-ACAGCGTTCGATAACTATGCGG-3′) and cdc-11 (5′-TGGAACATAGTCAGCTGGAAATTGATTCG-3′) with pDLB643 as a template. cdc-11 has a silent mutation which introduces a PvuII site (underlined). To generate pMOSB53 (cdc42-Y40C), PCR was performed using the oligonucleotides cdc-22 (5′-ACAGTGTTCGATAACTGTGCGGTGACTGTGATG-3′) and cdc-11 with pDLB643 as a template. To generate pMOSB29 (cdc42-D57Y), PCR was performed using the oligonucleotides cdc-18 (5′-TATACGGCCGGTCAAGAAG-3′) and cdc-19 (5′-AAACAAACCTAACGTATATGG-3′) with pDLB377 as a template. The mutants were sequenced to confirm the presence of the desired mutation and the absence of any other mutations.
To generate pMOSB176 and pMOSB177, PCR was performed using the oligonucleotides DJL42-3 (see above) and DJL42-6 (5′-CTACTACAGATATTACATGTGGCG-3′) to amplify
cdc42-Y40C (pMOSB53 template) or
cdc42-V36A (pMOSB16 template), respectively, and introduced into pDLB644 by gap repair. To generate pMOSB175 and pMOSB47, 2.1-kb
BamHI/
XhoI fragments containing
cdc42 alleles were excised from pMOSB176 and pMOSB177, respectively, and cloned into the corresponding sites of pRS314 (
45).
The
cdc42-V36A,
Q61L and
cdc42-Y40C,
Q61L alleles were generated by a two-step strategy in which we first removed residues 32 to 40 in
CDC42-Q61L and then employed homologous recombination to repair that “gap” with sequences from
cdc42-V36A or
cdc42-Y40C. We first replaced amino acids 32 to 40 in
CDC42-Q61L,
C188S with a
NotI site, using the ExSite PCR-based site-directed mutagenesis kit. PCR was performed with the oligonucleotides JMCDC42-1 (5′-CCGCGTCGGCTGGAAATTGATTCG-3′) and JMCDC42-2 (5′-CCGCGGTGACTGTGATGATTGG-3′) with pEG202-cdc42-Q61L,C188S (
46) as a template. The resulting allele was then transferred to pOBD.CYH using a PCR and gap repair strategy involving sequential amplification of the allele with the oligonucleotides LC20-CDC42 (5′-AATTCCAGCTGACCACCATGCAAACGCTAAAGTGTG-3′) and RC20-CDC42 (5′-GATCCCCGGGAATTGCCATGCTACAAAATTGTAGATTTT-3′) followed by a second PCR using the oligonucleotides BD70F and BD70R (
15) containing homology to the first primers and 70-nucleotide extensions with homology to pOBD.CYH. The resulting PCR product was transformed together with
PvuII/
NcoI-linearized pOBD.CYH into DLY1 to generate pOBD.CYH-cdc42-Q61L/C188S(Δ32–40) by gap repair.
cdc42-V36A and
cdc42-Y40C were then amplified by PCR using the oligonucleotides DJL42-3 and cdc-19 (see above) with pMOSB16 or pMOSB53 as a template and transformed into DLY1 together with
NotI-cut pOBD.CYH-cdc42-Q61L/C188S(Δ32–40) to generate the gap repair products pOBD.CYH-cdc42-V36A/Q61L/C188S and pOBD.CYH-cdc42-Y40C/Q61L/C188S.
Plasmids for the expression of myc-tagged alleles of
CDC42 in bacteria were made using the Univector system (
28).
CDC42 alleles were amplified by PCR using the oligonucleotides CDC42-UNI1 (5′-GGAATTC
CATATGCAAACGCTAAAGTGTGTTGTTGTC-3′; the
NdeI site is underlined, and the start codon is in boldface) and CDC42-UNI2 (5′-CC
GAGCTCCTACAAAATTGTACATTTTTTACTTTTC-3′; the
SacI site is underlined) with pGAL-CDC42(Q61L) (
55), pMOSB29, pOBD.CYH-cdc42-V36A/Q61L/C188S, or pOBD.CYH-cdc42-Y40C/Q61L/C188S as a template.
NdeI/
SacI-digested PCR fragments were cloned into the respective sites of pUNI-10 (
28), generating pDLB1034, -1035, -1160, and -1277. The pUNI-10-CDC42 plasmids were then recombined with pHB1-MYC3 using the Cre/lox system (
28) to produce the bacterial expression plasmids pDLB1234, -1235, -1240, and -1242. All constructs were sequenced to confirm that no changes occurred as a result of PCR manipulations.
To construct pG11-4,
STE11-4 was amplified by PCR and inserted downstream of the
GAL1 promoter in pRD53* as a
BamHI/
XhoI fragment; pRD53* is a derivative of pRD53 (
40) in which
URA3 lacks a
PstI site.
Plasmid pGS11ΔN-T was constructed by transferring the 3.5-kb
SacI/
XhoI fragment encoding
GAL1p-GST-STE11ΔN from pRD-STE11-H3 (
32) into the corresponding sites in pRS314 (
45).
Plasmid pPP828 is a
LEU2-marked derivative of pRL116 (
23) created by homologous recombination in yeast using pUC4-ura3::LEU2 (
31).
To express the Ste20p Cdc42p-Rac interactive binding (CRIB) domain as a recombinant glutathione S-transferase (GST) fusion protein, the oligonucleotides ste20-1 (5′-ATGTCATCTTCTATAACCACCGC-3′) and ste20-2 (5′-TGTTTGCAGGCGGTGTTG-3′) were used to amplify a DNA fragment encoding the Ste20p residues 328 to 428 by PCR using yeast genomic DNA as a template. The PCR fragment was cloned into pCR2.1 using the TA cloning kit (Invitrogen) and then excised using the flanking EcoRI sites and cloned into the EcoRI site of pGEX-KG, generating pGEX-Ste20CRIB. The construct was sequenced to confirm its orientation and that no PCR-induced mutations had occurred.
To generate the
ste20ΔCRIB allele (
23), the 3-kb
SphI/
KpnI fragment from pRS316-ste20(Δ334–369) (
23) was cloned into the corresponding sites of YIplac211 (
12), generating pMOSB134. pMOSB134 was digested at the unique
XbaI site within
STE20 (upstream of the deleted CRIB region) and transformed into DLY3067. Ura
+ transformants containing tandem
STE20-URA3-ste20ΔCRIB sequences were selected, and then “pop-out” events in which
URA3-containing sequences between the
STE20 and
ste20ΔCRIB genes were excised by homologous recombination were selected by plating them on 5-fluoroorotic acid. The colonies were screened by PCR using the oligonucleotide ste20-2 (5′-GAGTTTGCAGGCGGTGTTG-3′) and ste20-9 (5′-AACCGTCCAAGCCTGAAG-3′) to determine whether the excision event left
STE20 (558-bp PCR product) or
ste20ΔCRIB (446-bp PCR product) as the sole remaining allele.
Strains MOSY0023 and MOSY0106 were generated from a cross between MOSY0095 and BOY774 (
cla4::TRP1) or BOY489 (
ste20::TRP1), respectively. BOY489 and BOY774 were obtained from F. Cross (
6).
The
bem1::URA3 allele was generated by one-step gene replacement using an
EcoRI-
BamHI fragment from the plasmid pKO1 (
9).
Strain PPY911 (
40) contains a
HIS2-marked
FUS1-lacZ reporter integrated at the
FUS1 locus that was introduced by transformation of the
cdc42-1 strain DLY3032 with
SphI-digested pFL-HIS2. pFL-HIS2 contains a 2-kb
HIS2 HindIII fragment in place of the
HinddIII/
HindIII
TRP1 fragment in pFL-TRPb, which itself contains a 0.9-kb
TRP1 EcoRI/
StuI fragment (along with pBluescript polylinker sequences from
EcoRI-
HincII) in place of the
HindIII/
StuI
URA3 fragment of pSB286 (
39).
Production of recombinant proteins and binding assays. Wild-type and mutant myc-tagged CDC42 alleles were expressed in Escherichia coli BL21(DE3) (Stratagene). Extracts were prepared in bacterial lysis buffer (750 mM sucrose, 100 mM NaCl, 100 mM Tris-HCl [pH 8.0], 5 mM EDTA) containing the protease inhibitors aprotinin (7.5 μg/ml; Sigma, St. Louis, Mo.), pepstatin (5 μg/ml; Sigma), leupeptin (10 μg/ml; Boehringer Mannheim, Indianapolis, Ind.), and phenylmethylsulfonyl fluoride (0.5 mM; Sigma). The cells were treated with 2 mg of lysozyme/ml for 20 min on ice. To remove genomic DNA, MgCl2 was added to 15 mM and DNase I was added to 50 μg/ml. The cells were lysed by 20 min of incubation at 4°C with 2 mg of deoxycholic acid/ml. Insoluble material was removed by centrifugation at 4°C for 10 min. GST-Ste20-CRIB was expressed in the protease-deficient E. coli BL21, extracts were prepared as described above, and the protein was purified using glutathione Sepharose 4B (Amersham Pharmacia Biotech, Piscataway, N.J.) as specified by the manufacturer.
Binding assays were performed by incubating the bacterial extracts containing Cdc42p-myc with either GST or GST-Ste20-CRIB immobilized on glutathione beads in 200 μl of binding buffer (10 mM Tris-HCl [pH 7.5], 85 mM NaCl, 6 mM MgCl
2, 10% glycerol) at 4°C for 3 h. Binding reaction mixtures were washed three times at room temperature with wash buffer (10 mM Tris-HCl [pH 7.5], 10 mM MgCl
2, 1 mM dithiothreitol, 0.1% Triton X-100). Bead-bound proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted to Immobilon-P nylon membranes (Millipore, Bedford, Mass.), and immunoblotted with monoclonal anti-myc antibodies (9E10; Santa Cruz Biotechnology, Santa Cruz, Calif.) using standard procedures (
2). To confirm equal loading, the amount of GST-Ste20-CRIB in each lane was visualized by staining the membrane with India ink (
42).